Institute Director Leads New COVID-19 Clinical Study

October 19, 2020

Dr. Bill Powderly, the Larry J. Shapiro Director of the Institute for Public Health

The Larry J. Shapiro Director, Institute for Public Health, William G. Powderly, MD, associate dean for Clinical and Translational Sciences; co-director of the Washington University Division of Infectious Diseases and director of the Institute for Clinical and Translational Sciences, is principal investigator on a new study of anti-inflammatory drugs in COVID-19 patients. According to a university news release, the clinical trial is funded by the National Institutes of Health, and “aims to enroll 2,000 patients hospitalized with moderate to severe COVID-19, and is expected to last six months.”

Read the story in the Post-Dispatch, watch the story on KMOV-TV and hear a related story on St. Louis Public Radio with other WashU physicians involved in the study.